Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,038 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B. Desai J, et al. Among authors: solomon b. J Clin Oncol. 2020 Jul 1;38(19):2140-2150. doi: 10.1200/JCO.19.02654. Epub 2020 Mar 17. J Clin Oncol. 2020. PMID: 32182156 Free PMC article. Clinical Trial.
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.
Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, Wright GM, Wainer Z, Horvath LG, Boyer M, McCaughan B, Kohonen-Corish MR, Fox S, Cooper WA, Solomon B. Selinger CI, et al. Among authors: solomon b. Mod Pathol. 2013 Dec;26(12):1545-53. doi: 10.1038/modpathol.2013.87. Epub 2013 Jun 7. Mod Pathol. 2013. PMID: 23743928 Free article.
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Michael M, White SC, Abdi E, Nott L, Clingan P, Zimet A, Button P, Gregory D, Solomon B, Dobrovic A, Do H, Clarke S. Michael M, et al. Among authors: solomon b. Asia Pac J Clin Oncol. 2015 Mar;11(1):4-14. doi: 10.1111/ajco.12178. Epub 2014 Feb 27. Asia Pac J Clin Oncol. 2015. PMID: 24575793 Clinical Trial.
Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.
Itchins M, Chia PL, Hayes SA, Howell VM, Gill AJ, Cooper WA, John T, Mitchell P, Millward M, Clarke SJ, Solomon B, Pavlakis N. Itchins M, et al. Among authors: solomon b. Asia Pac J Clin Oncol. 2017 Aug;13 Suppl 3:3-13. doi: 10.1111/ajco.12754. Asia Pac J Clin Oncol. 2017. PMID: 28795492 Review.
1,038 results